Opdivo-话题@MedSci

#Opdivo#

81篇内容 | 2690人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1303054, encodeId=07b1130305427, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo单药治疗晚期肝癌是安全有效的（CheckMate 040）, objectType=article, longId=82634, objectId=30bb82634ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30bb82634ae, replyNumber=0, likeNumber=68, createdTime=2016-11-20, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30bb82634ae, moduleTitle=Opdivo单药治疗晚期肝癌是安全有效的（CheckMate 040）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30bb82634ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303053, encodeId=ab9e1303053c6, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=瘤免疫又一喜讯！SMC批准BMS旗下PD-1药物Opdivo与Yervoy联合用于晚期皮肤癌一线治疗, objectType=article, longId=82087, objectId=8c028208e2d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c028208e2d, replyNumber=0, likeNumber=69, createdTime=2016-11-11, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c028208e2d, moduleTitle=瘤免疫又一喜讯！SMC批准BMS旗下PD-1药物Opdivo与Yervoy联合用于晚期皮肤癌一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c028208e2d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303052, encodeId=304713030523e, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=肿瘤免疫组合疗法Opdivo/NKTR-214开展5种肿瘤治疗研究, objectType=article, longId=79023, objectId=848de9023d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=848de9023d1, replyNumber=0, likeNumber=96, createdTime=2016-10-01, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=848de9023d1, moduleTitle=肿瘤免疫组合疗法Opdivo/NKTR-214开展5种肿瘤治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=848de9023d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303051, encodeId=3258130305122, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=惊爆！Opdivo作为NSCLC一线用药试验未达终点！, objectType=article, longId=74596, objectId=ec59e4596cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec59e4596cf, replyNumber=0, likeNumber=0, createdTime=2016-08-07, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec59e4596cf, moduleTitle=惊爆！Opdivo作为NSCLC一线用药试验未达终点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec59e4596cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303050, encodeId=500e1303050cd, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=PD-1抗癌新药Opdivo与免疫疗法并用造成一名患者死亡, objectType=article, longId=73336, objectId=08c6e333651, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08c6e333651, replyNumber=0, likeNumber=92, createdTime=2016-07-22, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08c6e333651, moduleTitle=PD-1抗癌新药Opdivo与免疫疗法并用造成一名患者死亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08c6e333651)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303049, encodeId=ebb613030499a, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=百时美再受挫！NICE拒绝Opdivo用于肾癌治疗, objectType=article, longId=72296, objectId=be64e229622, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be64e229622, replyNumber=0, likeNumber=97, createdTime=2016-07-09, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be64e229622, moduleTitle=百时美再受挫！NICE拒绝Opdivo用于肾癌治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be64e229622)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303048, encodeId=22a8130304849, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=施贵宝Opdivo PK 默沙东Keytruda，肺癌市场谁胜出？, objectType=article, longId=71963, objectId=4b9fe1963d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b9fe1963d1, replyNumber=0, likeNumber=78, createdTime=2016-07-02, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b9fe1963d1, moduleTitle=施贵宝Opdivo PK 默沙东Keytruda，肺癌市场谁胜出？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b9fe1963d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303047, encodeId=b2b5130304eb4, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=百时美PD-1免疫疗法Opdivo斩获FDA第6个突破性药物资格——晚期膀胱癌, objectType=article, longId=71758, objectId=1026e1758e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1026e1758e7, replyNumber=0, likeNumber=99, createdTime=2016-06-30, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1026e1758e7, moduleTitle=百时美PD-1免疫疗法Opdivo斩获FDA第6个突破性药物资格——晚期膀胱癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1026e1758e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303046, encodeId=ecdf130304606, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=ASCO 2016：百时美免疫组合Opdivo+Yervoy一线治疗晚期非小细胞肺癌实现临床意义缓解, objectType=article, longId=70143, objectId=f4c4e01430f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4c4e01430f, replyNumber=0, likeNumber=62, createdTime=2016-06-08, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4c4e01430f, moduleTitle=ASCO 2016：百时美免疫组合Opdivo+Yervoy一线治疗晚期非小细胞肺癌实现临床意义缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4c4e01430f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303044, encodeId=c5921303044a1, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=百时美Opdivo治疗晚期非小细胞肺癌（NSCLC）具有极显著的持续总生存受益, objectType=article, longId=68857, objectId=a7e56885ecf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7e56885ecf, replyNumber=0, likeNumber=67, createdTime=2016-05-23, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7e56885ecf, moduleTitle=百时美Opdivo治疗晚期非小细胞肺癌（NSCLC）具有极显著的持续总生存受益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7e56885ecf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303045, encodeId=dc061303045ee, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=百时美Opdivo获FDA批准治疗经典型霍奇金淋巴瘤，成为全球治疗血液肿瘤的PD-1免疫疗法, objectType=article, longId=68860, objectId=f36f688604f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f36f688604f, replyNumber=0, likeNumber=84, createdTime=2016-05-23, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f36f688604f, moduleTitle=百时美Opdivo获FDA批准治疗经典型霍奇金淋巴瘤，成为全球治疗血液肿瘤的PD-1免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f36f688604f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303043, encodeId=35d61303043b5, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=FDA批准百时美Opdivo（nivolumab）治疗经典型霍奇金淋巴瘤, objectType=article, longId=68639, objectId=0895686396f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0895686396f, replyNumber=0, likeNumber=54, createdTime=2016-05-20, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0895686396f, moduleTitle=FDA批准百时美Opdivo（nivolumab）治疗经典型霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0895686396f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303042, encodeId=79b413030424f, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存, objectType=article, longId=67206, objectId=60226e206eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60226e206eb, replyNumber=0, likeNumber=79, createdTime=2016-04-28, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60226e206eb, moduleTitle=PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60226e206eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303041, encodeId=4f881303041eb, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=百时美PD-1免疫疗法Opdivo关键III期临床治疗头颈部鳞状细胞癌（SCCHN）大获成功, objectType=article, longId=66959, objectId=0eb56695937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0eb56695937, replyNumber=0, likeNumber=87, createdTime=2016-04-23, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0eb56695937, moduleTitle=百时美PD-1免疫疗法Opdivo关键III期临床治疗头颈部鳞状细胞癌（SCCHN）大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0eb56695937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303040, encodeId=5ff213030408c, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=FDA：PD-1免疫疗法Opdivo（nivolumab）再获批准——单药一线治疗BRAF野生型黑色素瘤, objectType=article, longId=59795, objectId=1be659e954c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1be659e954c, replyNumber=0, likeNumber=49, createdTime=2015-12-03, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1be659e954c, moduleTitle=FDA：PD-1免疫疗法Opdivo（nivolumab）再获批准——单药一线治疗BRAF野生型黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1be659e954c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303039, encodeId=b5a21303039cd, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=PD-1免疫疗法Opdivo治疗鳞状肺癌表现出持续生存获益（CheckMate-017，CheckMate-063研究）, objectType=article, longId=56040, objectId=67d956040cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67d956040cd, replyNumber=0, likeNumber=60, createdTime=2015-09-12, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67d956040cd, moduleTitle=PD-1免疫疗法Opdivo治疗鳞状肺癌表现出持续生存获益（CheckMate-017，CheckMate-063研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67d956040cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303038, encodeId=f7f4130303869, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=PD-1免疫疗法监管重大里程碑：百时美Opdivo获欧盟批准，系欧洲PD-1疗法, objectType=article, longId=52397, objectId=b2135239e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2135239e88, replyNumber=0, likeNumber=59, createdTime=2015-06-25, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2135239e88, moduleTitle=PD-1免疫疗法监管重大里程碑：百时美Opdivo获欧盟批准，系欧洲PD-1疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2135239e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303037, encodeId=ae1c130303e68, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=百时美免疫组合Opdivo+Yervoy一线治疗黑色素瘤获巨大成功, objectType=article, longId=49721, objectId=e31c49e21e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e31c49e21e9, replyNumber=0, likeNumber=77, createdTime=2015-04-24, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e31c49e21e9, moduleTitle=百时美免疫组合Opdivo+Yervoy一线治疗黑色素瘤获巨大成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e31c49e21e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303036, encodeId=2b7e1303036ff, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=FDA接受施贵宝PD-1抑制剂Opdivo治疗肺癌上市申请，免疫疗法进入主流实体瘤, objectType=article, longId=47602, objectId=c2b04e602af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2b04e602af, replyNumber=0, likeNumber=68, createdTime=2015-03-04, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2b04e602af, moduleTitle=FDA接受施贵宝PD-1抑制剂Opdivo治疗肺癌上市申请，免疫疗法进入主流实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2b04e602af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303035, encodeId=320e1303035cc, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=FDA提前三个月批准施贵宝PD-1抑制剂Nivolumab(Opdivo)，与Keytruda同价, objectType=article, longId=44538, objectId=2d0144538df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d0144538df, replyNumber=0, likeNumber=57, createdTime=2014-12-26, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d0144538df, moduleTitle=FDA提前三个月批准施贵宝PD-1抑制剂Nivolumab(Opdivo)，与Keytruda同价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d0144538df)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Opdivo

2020-05-29

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo单药治疗晚期肝癌是安全有效的（CheckMate 040）

2016-11-20

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

瘤免疫又一喜讯！SMC批准BMS旗下PD-1药物Opdivo与Yervoy联合用于晚期皮肤癌一线治疗

2016-11-11

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

肿瘤免疫组合疗法Opdivo/NKTR-214开展5种肿瘤治疗研究

2016-10-01

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

惊爆！Opdivo作为NSCLC一线用药试验未达终点！

2016-08-07

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

PD-1抗癌新药Opdivo与免疫疗法并用造成一名患者死亡

2016-07-22

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

百时美再受挫！NICE拒绝Opdivo用于肾癌治疗

2016-07-09

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

施贵宝Opdivo PK 默沙东Keytruda，肺癌市场谁胜出？

2016-07-02

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

百时美PD-1免疫疗法Opdivo斩获FDA第6个突破性药物资格——晚期膀胱癌

2016-06-30

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

ASCO 2016：百时美免疫组合Opdivo+Yervoy一线治疗晚期非小细胞肺癌实现临床意义缓解

2016-06-08

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

百时美Opdivo治疗晚期非小细胞肺癌（NSCLC）具有极显著的持续总生存受益

2016-05-23

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

百时美Opdivo获FDA批准治疗经典型霍奇金淋巴瘤，成为全球治疗血液肿瘤的PD-1免疫疗法

2016-05-23

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

FDA批准百时美Opdivo（nivolumab）治疗经典型霍奇金淋巴瘤

2016-05-20

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存

2016-04-28

heli0118 (审核中...)

前往app查看评论内容

#Opdivo#

百时美PD-1免疫疗法Opdivo关键III期临床治疗头颈部鳞状细胞癌（SCCHN）大获成功

2016-04-23

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

FDA：PD-1免疫疗法Opdivo（nivolumab）再获批准——单药一线治疗BRAF野生型黑色素瘤

2015-12-03

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

PD-1免疫疗法Opdivo治疗鳞状肺癌表现出持续生存获益（CheckMate-017，CheckMate-063研究）

2015-09-12

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

PD-1免疫疗法监管重大里程碑：百时美Opdivo获欧盟批准，系欧洲PD-1疗法

2015-06-25

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

百时美免疫组合Opdivo+Yervoy一线治疗黑色素瘤获巨大成功

2015-04-24

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

FDA接受施贵宝PD-1抑制剂Opdivo治疗肺癌上市申请，免疫疗法进入主流实体瘤

2015-03-04

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

FDA提前三个月批准施贵宝PD-1抑制剂Nivolumab(Opdivo)，与Keytruda同价

2014-12-26

科室
- - 订阅+
  - 更多科室
工具
服务